within Pharmacolibrary.Drugs.ATC.C;

model C07BB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.012966666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bisoprolol and thiazides is a fixed-dose combination medication containing bisoprolol, a selective beta-1 adrenergic blocker, and a thiazide diuretic (such as hydrochlorothiazide). It is used primarily for the management of hypertension when combination therapy is appropriate. Both components act synergistically to lower blood pressure. This combination is approved and used in several countries for antihypertensive therapy.</p><h4>Pharmacokinetics</h4><p>No population or fixed-combination pharmacokinetic studies are available for bisoprolol and thiazides (ATC C07BB07). Estimated parameters are generated from the known pharmacokinetics of bisoprolol and hydrochlorothiazide in healthy adult populations. Values reflect a typical fixed-dose oral regimen.</p><h4>References</h4><ol><li><p>Breithaupt-Grögler, K, et al., &amp; Belz, GG (2001). Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. <i>European journal of clinical pharmacology</i> 57(4) 275–284. DOI:<a href=&quot;https://doi.org/10.1007/s002280100323&quot;>10.1007/s002280100323</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11549204/&quot;>https://pubmed.ncbi.nlm.nih.gov/11549204</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07BB07;
